Showing results (1451-1460 of 19,550) with videos related to

Sort By:
Pageof 1,955
BMC Cancer|August 3, 2019
Valproic acid-induced amphiregulin secretion confers resistance to temozolomide treatment in human glioma cellsJui-Chieh Chen, I-Neng Lee, Cheng Huang, et al.
BMC Cancer|August 4, 2019
Acquired immunodeficiency associated with thymoma: a case reportTakahisa Kawamura, Tateaki Naito, Haruki Kobayashi, et al.
BMC Cancer|April 17, 2021
Effects of once-yearly zoledronic acid on bone density and incident vertebral fractures in nonmetastatic castration-sensitive prostate cancer patients with osteoporosisDaisuke Watanabe, Takahiro Kimura, Ken Watanabe, et al.
BMC Cancer|April 17, 2021
Comparing the characteristics and predicting the survival of patients with head and neck melanoma versus body melanoma: a population-based studyYuxin Ding, Runyi Jiang, Yuhong Chen, et al.
BMC Cancer|May 20, 2015
Benefit of adjuvant chemotherapy in patients with T4 UICC II colon cancerAndreas Teufel, Michael Gerken, Janine Hartl, et al.
BMC Cancer|May 20, 2015
Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasmsRobertson Mackenzie, Stefan Kommoss, Boris J Winterhoff, et al.
BMC Cancer|May 21, 2015
Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapyAtsushi Tomioka, Nobumichi Tanaka, Motokiyo Yoshikawa, et al.
BMC Cancer|May 22, 2015
Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: an open-label, multi-center, non-comparative phase II studyKun-Ming Rau, Yung-Chang Lin, Yen-Yang Chen, et al.
BMC Cancer|May 11, 2015
Increased risk of second primary malignancies following uterine cancer: a population-based study in Taiwan over a 30-year periodKuan-Der Lee, Chao-Yu Chen, Huei-Jean Huang, et al.
BMC Cancer|May 11, 2015
NBPF1, a tumor suppressor candidate in neuroblastoma, exerts growth inhibitory effects by inducing a G1 cell cycle arrestVanessa Andries, Karl Vandepoele, Katrien Staes, et al.
Pageof 1,955